M
Miguel J. A. Láinez
Researcher at Universidad Católica de Valencia San Vicente Mártir
Publications - 85
Citations - 11447
Miguel J. A. Láinez is an academic researcher from Universidad Católica de Valencia San Vicente Mártir. The author has contributed to research in topics: Migraine & Population. The author has an hindex of 29, co-authored 84 publications receiving 10263 citations. Previous affiliations of Miguel J. A. Láinez include University of Valencia & University of Chile.
Papers
More filters
Journal ArticleDOI
Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control.
Hans-Christoph Diener,Peer Tfelt-Hansen,Carl Dahlöf,Miguel J. A. Láinez,Giorgio Sandrini,Shuu Jiun Wang,Walter Neto,Ujjwalla Vijapurkar,Aiden Doyle,David Jacobs +9 more
TL;DR: It is demonstrated that TPM 100 mg/d is effective in migraine prophylaxis and was better tolerated than TPM 200mg/d, and was generally comparable to PROP.
Book ChapterDOI
Consensus for tinnitus patient assessment and treatment outcome measurement: Tinnitus Research Initiative meeting, Regensburg, July 2006.
Berthold Langguth,Ron Goodey,Andréia Aparecida de Azevedo,A. Bjorne,Anthony T. Cacace,A. Crocetti,L. Del Bo,Dirk De Ridder,I. Diges,Thomas Elbert,Herta Flor,C. Herraiz,T. Ganz Sanchez,Peter Eichhammer,Ricardo Rodrigues Figueiredo,Goeran Hajak,Tobias Kleinjung,Michael Landgrebe,Alain Londero,Miguel J. A. Láinez,Manuela Mazzoli,M.B. Meikle,Jennifer R. Melcher,Josef P. Rauschecker,Philipp G. Sand,Maren Struve,P. Van de Heyning,P. Van Dijk,R. Vergara +28 more
TL;DR: There is widespread recognition that consistency between research centres in the ways that patients with tinnitus are assessed and outcomes following interventions are measured would facilitate more effective co-operation and more meaningful evaluations and comparisons of outcomes.
Journal ArticleDOI
The neurology of COVID-19 revisited: A proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries.
Gustavo C. Román,Peter S. Spencer,J. Reis,Alain Buguet,Mostafa El Alaoui Faris,Sarosh M Katrak,Miguel J. A. Láinez,Marco T. Medina,Chandrashekhar Meshram,Hidehiro Mizusawa,Şerefnur Öztürk,Mohammad Wasay +11 more
TL;DR: A comprehensive review of the neurological disorders reported during the current COVID-19 pandemic demonstrates that infection with SARS-CoV-2 affects the central nervous system, the peripheral nervous system (PNS) and the muscle.
Journal ArticleDOI
Clinical benefits of early triptan therapy for migraine
TL;DR: A limited window of therapeutic opportunity exists early in an attack to improve the outcome of triptan treatment, and early intervention is recommended to avoid the significant pain and disability commonly associated with moderate or severe migraine.
Journal ArticleDOI
Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.
Markus Färkkilä,Hans-Christoph Diener,Gilles Géraud,Miguel J. A. Láinez,Jean Schoenen,Nadja Harner,Alison Pilgrim,Uwe Reuter +7 more
TL;DR: Oral lasmiditan seems to be safe and effective in the acute treatment of migraine and further assessment in larger placebo-controlled and triptan-controlled trials are needed.